Clinical trial

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05358249

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention JDQ443 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record trametinib Normalized identity: trametinibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Ribociclib Normalized identity: ribociclibView linked drug · Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention cetuximab Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2022-10-24

PhasePHASE1 / PHASE2

Conditions

KRAS G12C Mutant Solid Tumorsunresolved

Carcinoma, Non-Small Cell Lungcandidate · MONDO: non-small cell lung carcinoma

Carcinoma, Non-Small-Cell Lungcandidate · MONDO: non-small cell lung carcinoma

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Non-Small Cell Lung Carcinomaverified · MONDO: non-small cell lung carcinoma

Nonsmall Cell Lung Cancerverified · MONDO: tumor suppressor gene on chromosome 11

Colorectal Cancerverified · MONDO: colorectal cancer

Colorectal Carcinomaverified · MONDO: colorectal carcinoma

Colorectal Neoplasmsunresolved

Colorectal Tumorsunresolved

Neoplasms, Colorectalunresolved

Interventions

JDQ443DRUG

trametinibDRUG · verified · RxNorm: trametinib

RibociclibDRUG · verified · RxNorm: ribociclib

cetuximabBIOLOGICAL

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

BostonMassachusetts, United States2 MadridSpain2 New YorkNew York, United States1 SeoulSouth Korea1 BarcelonaSpain1 LyonFrance1 BordeauxFrance1 LeuvenBelgium1 SingaporeSingapore1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05358249 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.